ArticleCureus2019
The Beneficiary Role of Selenium in Type II Diabetes: A Longitudinal Study.
Article in Cureus, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Pooled it
- Nanocomposites of Opuntia ficus-indica mucilage-mediated selenium nanoparticles and nanochitosan as antidiabetic candidates in streptozocin-induced diabetic rats.Frontiers in bioengineering and biotechnology · 2026Article
- Selenium intake and risk of type 2 diabetes among adults in Saudi Arabia.Frontiers in endocrinology · 2025Article
- Therapeutic effects of selenium nanoparticles versus selenium on experimentally induced diabetic retinopathy via modulation of TLR4 / NF-Tissue barriers · 2025Article
- Mobile Application and Machine Learning-Driven Scheme for Intelligent Diabetes Progression Analysis and Management Using Multiple Risk Factors.Bioengineering (Basel, Switzerland) · 2024Article
- Selenium Species in Diabetes Mellitus Type 2.Biological trace element research · 2024Review
- Serum selenium and fasting blood glucose: a cross-sectional study in women of different menopause status.BMC women's health · 2024Article
- Article
- The Role of Fibrogenesis and Extracellular Matrix Proteins in the Pathogenesis of Graves' Ophthalmopathy.International journal of molecular sciences · 2024Review
- The Role of Glutathione and Its Precursors in Type 2 Diabetes.Antioxidants (Basel, Switzerland) · 2024Review
- 'Oxidative stress'-A new target in the management of diabetes mellitus.Journal of family medicine and primary care · 2023Review
- The Ethnopharmacological Properties of Green-Engineered Metallic Nanoparticles against Metabolic Disorders.Medicina (Kaunas, Lithuania) · 2023Review
- Article
- The Role of Oxidative Stress and Therapeutic Potential of Antioxidants in Graves' Ophthalmopathy.Biomedicines · 2021Review
- Fruits and Vegetables in the Management of Underlying Conditions for COVID-19 High-Risk Groups.Foods (Basel, Switzerland) · 2021Review
- Potential Health Risks of Macro- and Microelements in Commercial Medicinal Plants Used to Treatment of Diabetes.BioMed research international · 2021Article
- Selenium and RNA Virus Interactions: Potential Implications for SARS-CoV-2 Infection (COVID-19).Frontiers in nutrition · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Selenium (Se) is an antioxidotic element that is able to protect the pancreatic islets from oxidative stress, improve their functionality, and suspend atherosclerosis. The current paper is an attempt to demonstrate the beneficiary impact of administrating Se to patients with diabetes type 2 who are being treated with oral hypoglycemic agents, based on their glycemic and lipidemic profile. Methods The study involves 94 individuals, 72 male and 22 female patients aged 48 to 64 years old with diabetes mellitus type 2. They did not present any diabetic complications or significant comorbidities. They were following a Mediterranean diet and were monitored in order to maintain a steady body mass index (BMI). They were administered with Se 200 μg, taken once daily on an empty stomach. The laboratory testing included fasting blood glucose, hemoglobin A1c (HbA1c), total cholesterol, triglycerides, high-density lipoprotein (HDL), and low-density lipoprotein (LDL). The tests were performed before, three months after, and six months after the administration of selenium. Results The study resulted in a statistically significant reduction in the blood levels of glucose, HbA1c, cholesterol, and LDL in both three months and six months after the beginning of the treatment. HDL did not present any change during the first three months but did present a statistically significant increase in six months. Triglycerides did not present a significant reduction in both three and six months. Conclusion It appears that the administration of Se to type-2 diabetic patients can improve their glycemic and lipidemic profile, while larger definite trials are needed to provide further evidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.